梁 欢 贾垂明 王 燕 刘志强 刘 爱春.ICE 方案治疗复发难治性非霍奇金弥漫大 B 细胞淋巴瘤临床观察[J].,2015,15(2):274-276 |
ICE 方案治疗复发难治性非霍奇金弥漫大 B 细胞淋巴瘤临床观察 |
Recurrence of ICE Regimen for Refractory Non-Hodgkin's Diffuse Large BCell Lymphoma in Clinical Observation |
|
DOI: |
中文关键词: 非霍奇金弥漫大 B 细胞淋巴瘤 复发 / 难治 ICE 方案 |
英文关键词: Non-Hodgkin's lymphoma Relapsed /refractory ICE |
基金项目:黑龙江省教育厅科学研究项目( 1 154h13) |
|
摘要点击次数: 1037 |
全文下载次数: 3363 |
中文摘要: |
目 的: 观察 ICE 方案 (异环磷酰胺 IFO, 卡铂 CBP, 依托泊苷 VP-16) 治疗 复发 / 难治性非霍奇金弥漫大 B 细胞淋巴瘤
( Non-hodgkin's lymphoma, NHL) 的 疗 效及安全性。 方法: 20 例 经系 统化疗 后 复发或 进展的 非 霍 奇金弥漫大 B 细 胞淋巴 瘤
(DLBCL)患者, 采用 ICE 方案化疗 至少 2 周期, IFO 5 g/m2, 第 2 天, 持续 24 小时静脉输注, CBP 按 AUC=5, max 800 mg, 第 2 天,
静脉输注,VP-16. 100 mg/m2, 第 1 -3 天, 静脉输注。 结果: 完全缓解( complete response, CR)5 例, 部分缓解( partial response, PR)8
例, 疾病稳定( stable disease, SD)4 例, 疾病进展( progress disease, PD)3 例, 总有效率( overall response rate, ORR, CR+PR)65%, 化
疗 副 作用主要为 骨髓抑制( Ⅰ 、Ⅱ 度 6 例, Ⅲ 、Ⅳ 度 14 例), 其他不良反应包括胃 肠道反应、粘膜损伤、肝肾毒性及脱发等均可耐
受。 结论: ICE 方案可用 于非霍奇金弥漫大 B 细胞淋巴瘤的二线化疗方案。 |
英文摘要: |
Objective:To evaluate the safety and efficacy of the ifosfamide (IFO) combined with carboplatin (CBP) and vepeside
(VP-16) in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).Methods:Twenty patients with
conformed relapsed or refractory Non-hodgkin's lymphoma (NHL) were enrolled in this study. The chemotheraphy of regimen consisted
of IFO(5 g/m2, day 2, continue 24 h), carboplatin(CBP=5, max 800 mg, day 2), and vepeside(1 00 mg/m2, day 1-3).Results:In the twenty
cases,the complete response was in 5 cases, the partial response was in 8 cases, 4 cases was no change, 3 cases was progressive, and the
oveall reponse rate (CR+PR) was 65%. Side effect of chemotherapy mainly manifest as bone marrow suppression, while other adverse
reactions, including gastrointestinal reaction, mucosal injury, liver and kidney toxicity and hair loss, can be tolerated.Conclusion:ICE
regimen can achieve a safety result in the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL), and the toxicity was
tolerable |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|